再生元製藥公司 REGN 深 滬
等待開盤 03-26 09:30:00 美东时间
749.47
+7.780
+1.05%
華盛通- 最 高757.98
- 今 開744.67
- 成交量 55.31万股
- 最 低 744.02
- 昨 收 741.69
- 總市值 792.34亿
- 52周最高 820.17
- 市盈率 靜 18.07
- 換手率 0.52%
- 52周最低 473.7869
- 委 比 -68.87%
- 總股本 1.06亿
- 歷史最高 1206.7399
- 量 比 0.75
- 振 幅 1.88%
- 歷史最低 38.37
- 每 手 1
- 風險率 96.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多赛诺菲(SNY)股票3月25日盘中上涨3.33%：背后推手曝光
• FDA 授予 venglustat 治疗戈谢病的突破性疗法认定。 • 日本批准 Dupixent 用于治疗成人大疱性类天疱疮。 • 赛诺菲获得自身免疫性疾病抗体 KT501 的全球权益。
03-25 19:17
Japan MHLW approves Dupixent for moderate-to-severe bullous pemphigoid adults
Japan MHLW approves Dupixent for moderate-to-severe bullous pemphigoid adults Japan’s health ministry approved Dupixent (dupilumab) to treat adults with moderate-to-severe bullous pemphigoid, according to Regeneron and Sanofi. In the LIBERTY-BP-ADEPT Phase 2/3 trial, sustained disease remission at W
03-24 14:01
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
03-24 01:59
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment March 23 (Reuters) - Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi SASY.PA to develop the privately held firm's experimental treatment for several autoimmune diseases. H
03-23 19:51
UPDATE 3-Cencora buys EyeSouth's retina business in $1.1 billion deal
UPDATE 3-Cencora buys EyeSouth's retina business in $1.1 billion deal Adds analyst comments in paragraphs 6-7 By Padmanabhan Ananthan March 23 (Reuters) - U.S. drug distributor Cencora COR.N said on Monday it would buy the retina-care business of EyeSouth Partners for $1.1 billion, bolstering its sp
03-23 19:16
英伟达在美国缴纳170亿美元税款，居全球企业纳税额榜首
多家企业在新规申报文件中披露退税情况及在爱尔兰、马耳他的税务筹划 内容摘要 新会计准则要求企业详细披露现金缴纳税款情况，公开其在全球...
03-21 00:59
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
